Researchers have demonstrated that breast cancer can resurface 15 years after treatment, epigenetic editing has revealed a surprising insight into early breast cancer development and two breakthrough CDK4/6-inhibitor drugs have been approved for advanced breast cancer.
Researchers at the Ludwig Institute for Cancer Research (Brussels, Belgium) have discovered a novel mechanism used by tumors to evade immunotherapies.
A team of researchers have reported T cells survive a tumor’s anoxic environment and become more effective at killing cancer cells by exploiting HIF-1a and when they have access to growth factor VEGF-A.
This review describes trials evaluating the monoclonal antibody pembrolizumab (an immunotherapy that blocks the interaction between PD-L1/PD-L2) as first-line therapy for advanced non-small-cell lung cancer.
In this research article from the Journal of Comparative Effectiveness Research find out about the characteristics and treatment patterns among US patients with hairy cell leukemia.
This paper drives home the point that targeted and contextualized interventions are key to improving the quality of life of cancer survivors.